ArticleCell reports2021
HLA class-I-peptide stability mediates CD8
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Association of HLA class I allele and tuberculosis susceptibility: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8Oncoimmunology · 2026Article
- Conserved Influenza Epitopes Delivered via MHC-I-Functionalized Nanocarriers Induce Influenza-Specific CTL Responses.Immune network · 2026Article
- Article
- Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.Research square · 2026Article
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.bioRxiv : the preprint server for biology · 2026Article
- Human leukocyte antigen pharmacogenetics in infectious diseases: anti-infective drug toxicity and host immune response.Frontiers in pharmacology · 2026Review
- Immunopeptidomics can inform the design of mRNA vaccines for the delivery ofScience translational medicine · 2025Article
- Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1.iScience · 2025Article
- Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs.Scientific reports · 2025Article
- Article
- Deep learning enhances the prediction of HLA class I-presented CD8Nature machine intelligence · 2025Article
- Large-scale screening of HIV-1 T-cell epitopes restricted by 12 prevalent HLA-A allotypes in Northeast Asia and universal detection of HIV-1-specific CD8Frontiers in microbiology · 2025Article
- Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression.Journal for immunotherapy of cancer · 2024Article
- Tapasin assembly surveillance by the RNF185/Membralin ubiquitin ligase complex regulates MHC-I surface expression.Nature communications · 2024Article
- Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules.Structure (London, England : 1993) · 2024Article
- Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells.International journal of molecular sciences · 2024Article
- Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Clarety KasekeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ryan J ParkRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Harvard Radiation Oncology Program, Boston, MA 02114, USA.
Nishant K SinghRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Dylan KoundakjianRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Arman BashirovaBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Wilfredo F Garcia BeltranRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Overbeck C Takou MbahRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Jiaqi MaDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA.
Fernando SenjobeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Virology, Harvard Medical School, Boston, MA 02114, USA.
Jonathan M UrbachRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Anusha NathanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Elizabeth J RossinDepartment of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA; The Broad Institute, Cambridge, MA 02142, USA.
Rhoda Tano-MenkaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ashok KhatriMassachusetts General Hospital Endocrine Unit and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
Alicja Piechocka-TrochaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Michael T WaringRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Michael E BirnbaumRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Brian M BakerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; The Broad Institute, Cambridge, MA 02142, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Gaurav D GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: ggaiha@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USHoward Hughes Medical Institute · USBroad Institute · USHarvard University · USUniversity of Notre Dame · USFrederick National Laboratory for Cancer Research · US
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4MTissue Phenotyping CoreP01DK011794 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JUEPPNER, HARALD W. · 1986 to 2023
$44.4MEffects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2MStructural biophysics and molecular design in cellular immunityR35GM118166 · NIGMS · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2016 to 2025
$4.4MExploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7MUnderstanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV ReservoirsR01AI149704 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2020 to 2024
$2.1MCCR NIH HHS HHSN261200800001CHoward Hughes Medical InstituteNCI NIH HHS HHSN261200800001ENIAID NIH HHS DP2 AI154421NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI149704NIAID NIH HHS UM1 AI144462NIDDK NIH HHS P01 DK011794NIGMS NIH HHS R35 GM118166
Abstract
Defining factors that govern CD8
Indexed as
AllelesCD8-Positive T-LymphocytesFemaleHEK293 CellsHistocompatibility Antigens Class IHIV InfectionsHumansImmunodominant EpitopesPeptidesProtein DenaturationProtein StabilitySurface PropertiesHistocompatibility Antigens Class IImmunodominant EpitopesPeptidesCD8+ T cellsepitopesHIVHLAimmunodominancevaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.